In conclusion, our study demonstrated that circHERC4 could act as an oncogenic driver of CRC through a novel circHERC4/miR-556-5p/CTBP2/E-cadherin axis and could be exploited in cancer therapy. This evidence concerns the gene CTBP2 and cancer.